Related Experiment Videos
Pterygium surgery with mitomycin-C: ten-year results
1St. Croix Vision Center, Christiansted, Virgin Islands 00823, USA.
Abstract:
A review of 870 cases of primary and recurrent pterygia done between 1988 and 1998 by the merest sclera conjunctival flap technique with the single application of 0.1 cc of 0.4 mg/mL of mitomycin-C to the subconjunctival space is reported. There were 3 recurrences (0.35%) and no vision threatening complications. The adverse effects were mild and easily resolved with topical treatment.
Insights
A pterygium surgery review found the merest sclera conjunctival flap technique with mitomycin-C had a low recurrence rate of 0.35%. This safe method resulted in no vision-threatening complications and mild, treatable side effects.
Area of Science:
- Ophthalmology
- Surgical Techniques
Background:
- Pterygium is a common eye condition that can affect vision.
- Surgical intervention is often necessary for pterygium removal.
- Recurrence after pterygium surgery remains a clinical challenge.
Purpose of the Study:
- To evaluate the efficacy and safety of the merest sclera conjunctival flap technique combined with mitomycin-C for pterygium treatment.
- To assess the recurrence rates and complications associated with this surgical approach.
Main Methods:
- A retrospective review of 870 primary and recurrent pterygium cases.
- Surgical technique involved the merest sclera conjunctival flap.
- A single subconjunctival application of mitomycin-C (0.1 cc of 0.4 mg/mL) was administered.
Main Results:
- A low recurrence rate of 3 cases (0.35%) was observed.
- No vision-threatening complications were reported.
- Adverse effects were mild and resolved with topical treatment.
Conclusions:
- The merest sclera conjunctival flap technique with mitomycin-C is a highly effective and safe surgical option for pterygium.
- This method significantly reduces the risk of recurrence.
- The procedure is well-tolerated with minimal adverse effects.